<DOC>
	<DOC>NCT01518036</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (NorditropinÂ®) on final height in girls with Turner Syndrome.</brief_summary>
	<brief_title>Use of Somatropin in Turner Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<criteria>Turner Syndrome Not previously treated with growth hormone or androgen Welldocumented height over the previous 12 months Informed consent of parents (and child if appropriate) Growth hormone (GH) deficiency based on a GH stimulation test</criteria>
	<gender>Female</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>